Showing 2851-2860 of 5771 results for "".
- Surrozen Discontinues Liver Program; Shifts Focus to Ophthalmologyhttps://modernod.com/news/surrozen-discontinues-liver-program-shifts-focus-to-ophthalmology/2482716/Surrozen announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs, including development of new treatment options for retinopathies. The company will use a $175-million private placement
- Bausch + Lomb Publishes Phase 4 Data on the Early Effects of Miebo for Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-publishes-phase-4-data-on-the-early-effects-of-miebo-for-dry-eye-disease/2482715/Bausch + Lomb announced that Ophthalmology and Therapy has published results from a phase 4 study which assessed early patient-reported outcomes with Miebo in patients wit
- Electroretinography Added to AAO’s Diabetic Retinopathy Preferred Practice Pattern Guidelineshttps://modernod.com/news/electroretinography-added-to-aaos-diabetic-retinopathy-preferred-practice-pattern-guidelines/2482714/LKC Technologies, a provider of functional testing through electroretinography (ERG), announced that ERG has been included in the 2024 update of the American Academy of Ophthalmology’s (AAO) Preferred Practice Pattern (PPP) guidelines for diabetic
- Lighthouse Guild Appoints Thomas Panek as New President and CEOhttps://modernod.com/news/lighthouse-guild-appoints-thomas-panek-as-new-president-and-ceo/2482706/Lighthouse Guild announced this morning that Thomas Panek has been appointed as President and CEO, effective April 2025. He succeeds Dr. Calvin W. Roberts, who has served in this role for the past 5 years. Mr. Panek has significant leadership experience with a deep commitment to a
- Iluvien Earns FDA Approval for Expansion to Treat Chronic Posterior Uveitishttps://modernod.com/news/iluvien-earns-fda-approval-for-expansion-to-treat-chronic-posterior-uveitis/2482704/ANI Pharmaceuticals announced that they the FDA has approved an expanded label for Iluvien to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). “Iluvien's expanded label and the strengthening of our pa
- Harrow Launches 'Vevye Access for All' to Reduce Patient Barriers for Dry Eye Disease Treatmenthttps://modernod.com/news/harrow-launches-vevye-access-for-all-reducing-patient-barriers-for-dry-eye-disease-treatment/2482703/Harrow announced 'Vevye Access For All' – a new initiative that aims to reduce patient barriers to dry eye disease treatment. Harrow partnered with specialty pharmacy PhilRx to offer Vevye (cyclosporine ophthalmic solution) 0.1% for eligible patients at $59 a bottle. The g
- Bausch + Lomb Launches Arise Orthokeratology Lens System in the UShttps://modernod.com/news/bausch-lomb-announces-arisetm-orthokeratology-lens-system-in-the-united-states/2482702/Bausch + Lomb announced the US launch of Arise, a lens fitting system designed to use intelligent, cloud-based technology to streamline the orthokeratology lens design process. Orthokeratology is a non-surgical method of vision correction that uses rigid, gas-permea
- Atsena Granted FDA Fast Track Designation for Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-fast-track-designation-for-gene-therapy-to-treat-x-linked-retinoschisis/2482699/Atsena Therapeutics announced that the FDA has granted Fast Track designation for gene therapy product candidate, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of g
- Study Finds Most Glaucoma Patients Unaware of Preservative-Free Treatment Optionshttps://modernod.com/news/60-of-glaucoma-patients-unaware-of-preservative-free-treatment-options-study-from-preservative-freedom-coalition/2482698/The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers. This comes as Monday kicked o
- First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDhttps://modernod.com/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd/2482694/4D Molecular Therapeutics (4DMT) announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (AMD). "This is a historic moment for 4DMT as we becom